Japan · Delayed Price · Currency is JPY Sumitomo Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY2025 saw strong revenue and profit growth, driven by North American product sales and cost controls. Full-year guidance is unchanged due to expected Q4 seasonality, while oncology R&D and partnering timelines have shifted to maximize asset value.
-
Q2 FY2025 saw revenue and profit surge above forecasts, driven by strong North America sales, a JPY 49 billion gain from the China-Asia business transfer, and disciplined cost control. Full-year guidance was raised, with Orgovyx expected to surpass $1 billion in sales.
-
Q1 FY2025 saw strong revenue and profit growth, led by North America, with ORGOVYX and GEMTESA outperforming plans. Full-year guidance is unchanged due to uncertainties, but significant one-time gains are expected in H1. R&D and governance initiatives continue to advance.
Fiscal Year 2025
-
FY 2024 saw a strong recovery with revenue up 27% year-over-year, driven by U.S. product growth and major cost reductions. FY 2025 guidance anticipates lower revenue due to business transfers and loss of exclusivity, but higher core operating profit and continued focus on key products.
-
Returned to profitability with strong revenue growth and cost reductions, raising full-year forecasts. North American products outperformed, while Japan faced headwinds from loss of exclusivity. Ongoing refinancing and R&D prioritization continue.